919
Views
26
CrossRef citations to date
0
Altmetric
Reviews

Prognostic value of neuron-specific enolase (NSE) for prediction of post-concussion symptoms following a mild traumatic brain injury: a systematic review

, , , , , , , , & show all
Pages 29-40 | Received 15 Feb 2017, Accepted 24 Sep 2017, Published online: 20 Nov 2017

References

  • Roozenbeek B, Maas AI, Menon DK. Changing patterns in the epidemiology of traumatic brain injury. Nat Reviews Neurol. 2013;9(4):231–36. doi:10.1038/nrneurol.2013.22.
  • Langlois JA, Rutland-Brown W, Wald MM. The epidemiology and impact of traumatic brain injury: A brief overview. J Head Trauma Rehabil. 2006;21(5):375–78. doi:10.1097/00001199-200609000-00001.
  • Nguyen R, Fiest KM, McChesney J, Kwon CS, Jette N, Frolkis AD, Atta C, Mah S, Dhaliwal H, Reid A, et al. The international incidence of traumatic brain injury: A systematic review and meta-analysis. Can J Neurol Sci. 2016;43(6):774–85.
  • Scholten AC, Haagsma JA, Andriessen TM, Vos PE, Steyerberg EW, van Beeck EF, Polinder S. Health-related quality of life after mild, moderate and severe traumatic brain injury: patterns and predictors of suboptimal functioning during the first year after injury. Injury. 2015;46(4):616–24. doi:10.1016/j.injury.2014.10.064.
  • van der Naalt J, van Zomeren AH, Sluiter WJ, Minderhoud JM. One year outcome in mild to moderate head injury: the predictive value of acute injury characteristics related to complaints and return to work. J Neurol Neurosurg Psychiatry. 1999;66(2):207–13. doi:10.1136/jnnp.66.2.207.
  • Sirois MJ, Emond M, Ouellet MC, Perry J, Daoust R, Morin J, Dionne C, Camden S, Moore L, Allain-Boule N. Cumulative incidence of functional decline after minor injuries in previously independent older canadian individuals in the emergency department. J Am Geriatr Soc. 2013;61(10):1661–68. doi:10.1111/jgs.12482.
  • Brousseau AA, Emond M, Sirois MJ, Daoust R, Griffith LE, Lang E, Lee J, Perry JJ, Ouellet MC, Verreault R, et al. Comparison of functional outcomes in elderly who have sustained a minor trauma with or without head injury: A prospective multicenter cohort study. CJEM. 2017 Sep;19(5):329–37.
  • Dahm J, Ponsford J. Comparison of long-term outcomes following traumatic injury: what is the unique experience for those with brain injury compared with orthopaedic injury? Injury. 2015;46(1):142–49. doi:10.1016/j.injury.2014.07.012.
  • Bombardier CH, Hoekstra T, Dikmen S, Fann JR. Depression trajectories during the first year after traumatic brain injury. J Neurotrauma. 2016;33:2115–24. doi:10.1089/neu.2015.4349.
  • Bryan CJ, Clemans TA. Repetitive traumatic brain injury, psychological symptoms, and suicide risk in a clinical sample of deployed military personnel. JAMA Psychiatry. 2013;70(7):686–91. doi:10.1001/jamapsychiatry.2013.1093.
  • Mercier E, Mitra B, Cameron PA. Challenges in assessment of the mild traumatic brain injured geriatric patient. Injury. 2016;47(5):985–87. doi:10.1016/j.injury.2016.04.001.
  • Zitnay GA, Zitnay KM, Povlishock JT, Hall ED, Marion DW, Trudel T, Zafonte RD, Zasler N, Nidiffer FD, DaVanzo J, et al. Traumatic brain injury research priorities: the conemaugh international brain injury symposium. J Neurotrauma. 2008;25(10):1135–52. doi:10.1089/neu.2008.0599.
  • Kulbe JR, Geddes JW. Current status of fluid biomarkers in mild traumatic brain injury. Exp Neurol. 2016;275(Pt 3):334–52. doi:10.1016/j.expneurol.2015.05.004.
  • Manley GT, Diaz-Arrastia R, Brophy M, Engel D, Goodman C, Gwinn K, Veenstra TD, Ling G, Ottens AK, Tortella F, et al. Common data elements for traumatic brain injury: recommendations from the biospecimens and biomarkers working group. Arch Phys Med Rehabil. 2010;91(11):1667–72. doi:10.1016/j.apmr.2010.05.018.
  • Skogseid IM, Nordby HK, Urdal P, Paus E, Lilleaas F. Increased serum creatine kinase bb and neuron specific enolase following head injury indicates brain damage. Acta Neurochir (Wien). 1992;115(3–4):106–11. doi:10.1007/BF01406367.
  • Isgro MA, Bottoni P, Scatena R. Neuron-specific enolase as a biomarker: biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:125–43.
  • Jeter CB, Hergenroeder GW, Hylin MJ, Redell JB, Moore AN, Dash PK. Biomarkers for the diagnosis and prognosis of mild traumatic brain injury/concussion. J Neurotrauma. 2013;30(8):657–70. doi:10.1089/neu.2012.2439.
  • Plog BA, Dashnaw ML, Hitomi E, Peng W, Liao Y, Lou N, Deane R, Nedergaard M. Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system. J Neurosci. 2015;35(2):518–26. doi:10.1523/JNEUROSCI.3742-14.2015.
  • Scolletta S, Donadello K, Santonocito C, Franchi F, Taccone FS. Biomarkers as predictors of outcome after cardiac arrest. Expert Rev Clin Pharmacol. 2012;5(6):687–99. doi:10.1586/ecp.12.64.
  • Woertgen C, Rothoerl RD, Holzschuh M, Metz C, Brawanski A. Comparison of serial s-100 and nse serum measurements after severe head injury. Acta Neurochir (Wien). 1997;139(12):1161–65. doi:10.1007/BF01410977.
  • Raabe A, Grolms C, Seifert V. Serum markers of brain damage and outcome prediction in patients after severe head injury. Br J Neurosurg. 1999;13(1):56–59. doi:10.1080/02688699944195.
  • Pleines UE, Morganti-Kossmann MC, Rancan M, Joller H, Trentz O, Kossmann T. S-100 beta reflects the extent of injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury. J Neurotrauma. 2001;18(5):491–98. doi:10.1089/089771501300227297.
  • Kukacka J, Vajtr D, Huska D, Prusa R, Houstava L, Samal F, Diopan V, Kotaska K, Kizek R. Blood metallothionein, neuron specific enolase, and protein s100b in patients with traumatic brain injury. Neuro Endocrinol Lett. 2006;27(Suppl 2):116–20.
  • Herrmann M, Curio N, Jost S, Wunderlich MT, Synowitz H, Wallesch CW. Protein s-100b and neuron specific enolase as early neurobiochemical markers of the severity of traumatic brain injury. Restor Neurol Neurosci. 1999;14(2):109–14.
  • Herrmann M, Jost S, Kutz S, Ebert AD, Kratz T, Wunderlich MT, Synowitz H. Temporal profile of release of neurobiochemical markers of brain damage after traumatic brain injury is associated with intracranial pathology as demonstrated in cranial computerized tomography. J Neurotrauma. 2000;17(2):113–22. doi:10.1089/neu.2000.17.113.
  • Mussack T, Biberthaler P, Kanz KG, Heckl U, Gruber R, Linsenmaier U, Mutschler W, Jochum M. Immediate s-100b and neuron-specific enolase plasma measurements for rapid evaluation of primary brain damage in alcohol-intoxicated, minor head-injured patients. Shock. 2002;18(5):395–400. doi:10.1097/00024382-200211000-00002.
  • Marangos PJ, Schmechel DE. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu Rev Neurosci. 1987;10:269–95. doi:10.1146/annurev.ne.10.030187.001413.
  • Mercier E, Boutin A, Shemilt M, Lauzier F, Zarychanski R, Fergusson DA, Moore L, McIntyre A, Archambault P, Légaré F, et al. Predictive value of neuron-specific enolase for prognosis in patients with moderate or severe traumatic brain injury: A systematic review and meta-analysis. Cmaj Open. 2016;4(3):E371–E382. doi:10.9778/cmajo.20150061.
  • Bandyopadhyay S, Hennes H, Gorelick MH, Wells RG, Walsh-Kelly CM. Serum neuron-specific enolase as a predictor of short-term outcome in children with closed traumatic brain injury. Acad Emerg Med. 2005;12(8):732–38. doi:10.1111/acem.2005.12.issue-8.
  • Katz DI, Cohen SI, Alexander MP. Mild traumatic brain injury. Handb Clin Neurol. 2015;127:131–56.
  • Maas AI, Lingsma HF, Roozenbeek B. Predicting outcome after traumatic brain injury. Handb Clin Neurol. 2015;128:455–74.
  • Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280–86. doi:10.7326/0003-4819-158-4-201302190-00009.
  • von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (strobe) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–49. doi:10.1016/j.jclinepi.2007.11.008.
  • Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, Group -P-P. Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: elaboration and explanation. BMJ (Clinical Research Ed). 2015;349:g7647.
  • Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical Research Ed). 2009;339:b2700. doi:10.1136/bmj.b2700.
  • Herrmann M, Curio N, Jost S, Grubich C, Ebert AD, Fork ML, Synowitz H. Release of biochemical markers of damage to neuronal and glial brain tissue is associated with short and long term neuropsychological outcome after traumatic brain injury. J Neurol Neurosurg Psychiatry. 2001;70(1):95–100. doi:10.1136/jnnp.70.1.95.
  • de Kruijk JR, Leffers P, Menheere PPCA, Meerhoff S, Rutten J, Twijnstra A. Prediction of post-traumatic complaints after mild traumatic brain injury: early symptoms and biochemical markers. J Neurol Neurosurg Psychiatry. 2002;73(6):727–32. doi:10.1136/jnnp.73.6.727.
  • de Kruijk JR, Leffers P, Menheere PPC, Meerhoff S, Rutten J, Twijnstra A. Olfactory function after mild traumatic brain injury. Brain Injury. 2003;17(1):73–78 76p. doi:10.1080/0269905021000010221.
  • Stålnacke B, Björnstig U, Karlsson K, Sojka P. One-year follow-up of mild traumatic brain injury: post-concussion symptoms, disabilities and life satisfaction in relation to serum levels of s-100b and neurone-specific enolase in acute phase. J Rehabil Med (Taylor Francis Ltd). 2005;37(5):300–305 306p. doi:10.1080/16501970510032910.
  • Naeimi ZS, Weinhofer A, Sarahrudi K, Heinz T, Vécsei V. Predictive value of s-100b protein and neuron specific-enolase as markers of traumatic brain damage in clinical use. Brain Injury. 2006;20(5):463–68. doi:10.1080/02699050600664418.
  • Sojka P, Stalnacke BM, Bjornstig U, Karlsson K. One-year follow-up of patients with mild traumatic brain injury: occurrence of post-traumatic stress-related symptoms at follow-up and serum levels of cortisol, s-100b and neuron-specific enolase in acute phase. Brain Injury. 2006;20(6):613–20. doi:10.1080/02699050600676982.
  • Stalnacke BM, Elgh E, Sojka P. One-year follow-up of mild traumatic brain injury: cognition, disability and life satisfaction of patients seeking consultation. J Rehabil Med. 2007;39(5):405–11. doi:10.2340/16501977-0057.
  • Schutze M, Kundt G, Buchholz K, Piek J. [which factors are predictive for long-term complaints after mild traumatic brain injuries?]. Versicherungsmedizin. 2008;60(2):78–83.
  • Meric E, Gunduz A, Turedi S, Cakir E, Yandi M. The prognostic value of neuron-specific enolase in head trauma patients. J Emerg Med. 2010;38(3):297–301. doi:10.1016/j.jemermed.2007.11.032.
  • Topolovec-Vranic J, Pollmann-Mudryj MA, Ouchterlony D, Klein D, Spence J, Romaschin A, Rhind S, Tien HC, Baker AJ. The value of serum biomarkers in prediction models of outcome after mild traumatic brain injury. J Trauma-Injury Infect Crit Care. 2011;71:S478–S486. doi:10.1097/TA.0b013e318232fa70.
  • Shahim P, Tegner Y, Wilson DH, Randall J, Skillback T, Pazooki D, Kallberg B, Blennow K, Zetterberg H. Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol. 2014;71(6):684–92. doi:10.1001/jamaneurol.2014.367.
  • Thelin EP, Jeppsson E, Frostell A, Svensson M, Mondello S, Bellander BM, Nelson DW. Utility of neuron-specific enolase in traumatic brain injury; relations to s100b levels, outcome, and extracranial injury severity. Critical Care (London, England). 2016;20:285. doi:10.1186/s13054-016-1450-y.
  • Yokobori S, Hosein K, Burks S, Sharma I, Gajavelli S, Bullock R. Biomarkers for the clinical differential diagnosis in traumatic brain injury–a systematic review. CNS Neurosci Ther. 2013;19(8):556–65. doi:10.1111/cns.12127.
  • Wolf H, Krall C, Pajenda G, Hajdu S, Widhalm H, Leitgeb J, Sarahrudi K. Preliminary findings on biomarker levels from extracerebral sources in patients undergoing trauma surgery: potential implications for tbi outcome studies. Brain Injury. 2016;30(10):1220–25. doi:10.3109/02699052.2016.1170883.
  • Ercole A, Thelin EP, Holst A, Bellander BM, Nelson DW. Kinetic modelling of serum s100b after traumatic brain injury. BMC Neurol. 2016;16:93. doi:10.1186/s12883-016-0614-3.
  • Isokuortti H, Iverson GL, Kataja A, Brander A, Ohman J, Luoto TM. Who gets head trauma or recruited in mild traumatic brain injury research? J Neurotrauma. 2016;33(2):232–41. doi:10.1089/neu.2015.3888.
  • Luoto TM, Tenovuo O, Kataja A, Brander A, Ohman J, Iverson GL. Who gets recruited in mild traumatic brain injury research? J Neurotrauma. 2013;30(1):11–16. doi:10.1089/neu.2012.2611.
  • Honda M, Tsuruta R, Kaneko T, Kasaoka S, Yagi T, Todani M, Fujita M, Izumi T, Maekawa T. Serum glial fibrillary acidic protein is a highly specific biomarker for traumatic brain injury in humans compared with s-100b and neuron-specific enolase. J Trauma. 2010;69(1):104–09. doi:10.1097/TA.0b013e3181bbd485.
  • Saatman KE, Duhaime AC, Bullock R, Maas AI, Valadka A, Manley GT. Classification of traumatic brain injury for targeted therapies. J Neurotrauma. 2008;25(7):719–38. doi:10.1089/neu.2008.0586.
  • Dey S, Gangadharan J, Deepika A, Kumar JK, Christopher R, Ramesh SS, Devi BI, Shukla DP. Correlation of ubiquitin c terminal hydrolase and s100beta with cognitive deficits in young adults with mild traumatic brain injury. Neurology India. 2017;65(4):761–66. doi:10.4103/neuroindia.NI_884_15.
  • Bazarian JJ, Zemlan FP, Mookerjee S, Stigbrand T. Serum s-100b and cleaved-tau are poor predictors of long-term outcome after mild traumatic brain injury. Brain Injury. 2006;20(7):759–65. doi:10.1080/02699050500488207.
  • Metting Z, Wilczak N, Rodiger LA, Schaaf JM, van der Naalt J. Gfap and s100b in the acute phase of mild traumatic brain injury. Neurology. 2012;78(18):1428–33. doi:10.1212/WNL.0b013e318253d5c7.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.